Kodiak Sciences
KOD
91.08
-1.26
-1.36%
Kodiak Sciences
US · KOD
#1934 by market cap
Listed 2018
91.08
-1.26
-1.36%
Live - 5344 symbols - heartbeat 546s ago
· 2026-10-08 08:07
Pre-market
90.52
-0.61%
After-hours
91.08
0.00%
Overnight
90.38
-0.77%
- Market cap
- 5.72B
- P/E (TTM)i
- -21.74
- P/Bi
- 93.70
- EPSi
- -4.32
- Div yieldi
- 0.00%
- 52W posi
- 86%
Reader sentiment
Are you bullish or bearish on KOD?
Anonymous reader poll. Unscientific, not investment advice.
About Kodiak Sciences
Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.
- Founded
- 2009
- CEO
- Dr. Victor Perlroth, M.D.
- Employees
- 124
- Headquarters
- Palo Alto, California, United States of America
- Fiscal year end
- 12-31
- Website
- kodiak.com
Company profile
- Exchange
- US
- Symbol
- KOD
- Market-cap rank
- #1934
- Listing date
- 2018-10-04
- Market cap
- 5.72B
- Float cap
- 3.37B
- Shares out
- 62.85M
- Float shares
- 36.99M
Sectors & themes
Quote time 2026-10-08 08:07:35 · For reference only, not investment advice and not tailored to your situation.